Announcements Trials
Browse Landscape

Phase

Phase 1 3Phase 2 2

Status

Completed 5Active not recruiting 1

Sponsor Class

INDUSTRY 3NIH 2

Study Type

Interventional 5

Sponsor

Cancer Type

Thoracic 13Gynecologic 13Gastrointestinal 12Sarcoma 9CNS 8Genitourinary 6Tumor-Agnostic 5Other solid neoplasm 5Other hematologic neoplasm 5Breast 5Head & Neck 3Lymphoid 2Dermatologic 2Plasma cell 1Endocrine 1

Conditions

Advanced Solid Tumor 3Solitary Fibrous Tumor, Pleural 2Mesothelioma, Malignant 2

Interventions

Cisplatin 81Gemcitabine 58Carboplatin 57Irinotecan 56Paclitaxel 53Pemetrexed 47Docetaxel 39Nivolumab 33Fluorouracil 30Bevacizumab 27pembrolizumab 25Cyclophosphamide 24Capecitabine 24Oxaliplatin 22Leucovorin 21Topotecan 19durvalumab 17Erlotinib Hydrochloride 17Sorafenib 16Everolimus 16Etoposide 16Bortezomib 16Ipilimumab 15Injections 15Sunitinib 14Filgrastim 14Early Intervention, Educational 14atezolizumab 13alvocidib 13Sirolimus 13

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

5 trials
RecentStart dateEnrollment
Completed × cediranib × Other solid neoplasm × Clear all
NCT00243074 2018-01-23

S0509 - AZD2171 in Treating Patients With Malignant Pleural Mesothelioma That Cannot Be Removed By Surgery

National Cancer Institute (NCI)

Phase 2 Completed
54 enrolled 12 charts
Other solid neoplasmThoracic

Mesothelioma, Malignant, Solitary Fibrous Tumor, Pleural

NCT00309946 2014-07-31

Cediranib Maleate in Treating Patients With Malignant Mesothelioma That Cannot Be Removed By Surgery

National Cancer Institute (NCI)

Phase 2 Completed
51 enrolled 5 charts
Other solid neoplasmThoracic

Mesothelioma, Malignant, Solitary Fibrous Tumor, Pleural

NCT00502567 2011-07-27

A Study to Assess Safety, Tolerability and PK of AZD2171 and Chemotherapy on Patients With Solid Tumors

AstraZeneca

Phase 1 Completed
104 enrolled
Other solid neoplasm

Advanced Solid Tumor

NCT00501605 2011-01-21

Phase I Study With AZD2171 in Patients With Advanced Solid Malignant Tumors and Liver Metastases

AstraZeneca

Phase 1 Completed
80 enrolled
Other solid neoplasm

Advanced Solid Tumor

NCT00503477 2009-06-12

A Phase I Open Label Dose Escalation Study for the Safety and Tolerability of AZD2171 in Solid Tumors in Japan

AstraZeneca

Phase 1 Completed
40 enrolled
Other solid neoplasm

Advanced Solid Tumor

Data powered by HemOnc (CC BY 4.0) Colophon âš¡